✦ LIBER ✦

Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients

✍ Scribed by Takashima, Shuichiro; Miyamoto, Toshihiro; Kadowaki, Masanori; Ito, Yoshikiyo; Aoki, Takatoshi; Takase, Ken; Shima, Takahiro; Yoshimoto, Goichi; Kato, Koji; Muta, Tsuyoshi; Shiratsuchi, Motoaki; Takenaka, Katsuto; Iwasaki, Hiromi; Teshima, Takanori; Kamimura, Tomohiko; Akashi, Koichi

Book ID: 125379046
Publisher: Carden Jennings Publishing
Year: 2014
Tongue: English
Weight: 185 KB
Volume: 100
Category: Article
ISSN: 0925-5710
DOI: 10.1007/s12185-014-1611-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sequential Bortezomib, Dexamethasone, an

Sequential Bortezomib, Dexamethasone, and Thalidomide Maintenance Therapy after Single Autologous Peripheral Stem Cell Transplantation in Patients with Multiple Myeloma

✍ Firoozeh Sahebi; Paul H. Frankel; Len Farol; Amrita Y. Krishnan; Ji-lian Cai; Ge 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 110 KB

Bortezomib with thalidomide plus dexamet

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

✍ Michele Cavo; Paola Tacchetti; Francesca Patriarca; Maria Teresa Petrucci; Lucia 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 276 KB

Sequential vincristine, adriamycin, dexa

Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial

✍ Hye Jin Kim; Sung-Soo Yoon; Dong Soon Lee; Sang Kyun Sohn; Hyeon Seok Eom; Jung 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 184 KB

First-line thalidomide–dexamethasone the

First-line thalidomide–dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma

✍ Abdelkefi, A; Torjman, L; Ben Romdhane, N; Ladeb, S; El Omri, H; Ben Othman, T; 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 139 KB

Thalidomide plus dexamethasone as a main

Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma

✍ Angelo Maiolino; Vania T.M. Hungria; Marcia Garnica; Gislaine Oliveira-Duarte; L 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 443 KB

Thalidomide-Dexamethasone as Induction T

Thalidomide-Dexamethasone as Induction Therapy before Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma and Renal Insufficiency

✍ Patrizia Tosi; Elena Zamagni; Paola Tacchetti; Michela Ceccolini; Giulia Perrone 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 345 KB